CHEK2 and breast carcinoma: CHEK2 pathogenic variant carriers are an important group of women to identify as they are at an increased risk of contralateral breast cancer and have a lower survival compared with non-CHEK2 pathogenic variant carriers (these data are predominantly informed by information about CHEK2 c.1100delC17–22) and could benefit from specific screening modalities such as magnetic resonance imaging23.